China National Biotech Group, another Chinese vaccine company, is offering its vaccine free to students who study overseas in a strategy health experts say raises safety and ethical concerns.
"Before giving permission, the drugs regulator will conduct a technical evaluation of the application submitted by Dr Reddy's lab to conduct phase 2,3 clinical trial in India of Russian COVID-19 vaccine", said the official.
Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said.
"The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic", a statement from the Russian fund had earlier stated.
A business news website called Star Market Daily reported Monday that anyone could log on to the CNBG website to get the vaccine.
BBIBP-CorV is one of at least 10 coronavirus vaccine projects globally to have entered Phase 3 trials, four of which are led by Chinese scientists, according to the World Health Organisation.
The results came from a combined Phase I and Phase II trial involving more than 600 healthy adults conducted between April 29 and July 30.
Since the start of the pandemic, Russian Federation has recorded more than 1,340,000 infections, fourth in the world behind the United States, India and Brazil.
The COVAX is a global initiative aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines, once they are licensed and approved.
The U.S.is attempting to fast-track vaccine development too, after U.S. President Donald Trump authorized Operation Warp Speed in April to support companies with federal funding.
A Chinese city is offering Sinovac Biotech's experimental Covid-19 vaccine to essential workers and other high-risk groups as part of a national programme for about $60 (RM 249).
The SII is testing the vaccine developed by the Oxford University and AstraZeneca in India.
Some potential vaccines have run into hurdles during Phase 3.
According to the news source, a large-scale human trial of EpiVacCorona is likely to begin in November or December. The head of Rospotrebnadzor, Anna Popova, said she already received the inoculation and felt no side effects.
Mankind pharma has collaborated with the Russian Direct Investment Fund (RDIF) for sale and distribution of Russian vaccine Sputnik V in India.